Previcox is a brand-name tablet containing firocoxib, a nonsteroidal anti-inflammatory drug (NSAID) originally approved for dogs but widely used off-label in horses to manage pain and inflammation from osteoarthritis, soft-tissue injuries, and post-surgical recovery. The FDA-approved equine formulation of firocoxib is actually sold under a different name, Equioxx, as an oral paste or injectable. Previcox tablets became popular in equine practice because they contain the same active ingredient at a lower cost per dose, though their use in horses falls outside the manufacturer’s labeled indications. Understanding why veterinarians reach for this drug, how it differs from older pain relievers, and what risks come with it helps you make better decisions alongside your vet.
Why Firocoxib Instead of Older NSAIDs
Horses have long been treated with traditional NSAIDs like phenylbutazone (“bute”) and flunixin meglumine (“Banamine”). Those drugs work, but they block both major forms of cyclooxygenase, the enzyme family responsible for producing prostaglandins. One form, COX-1, handles everyday housekeeping in the gut lining, kidneys, and platelets. The other, COX-2, ramps up during injury and drives the pain-and-swelling response. Blocking both at once controls inflammation but also strips away the protective prostaglandins that keep the stomach and intestinal lining intact.
Firocoxib belongs to a newer class called coxibs, which are far more selective for COX-2. In horses, its selectivity ratio is roughly 643 to 1, meaning it inhibits the inflammation-driving enzyme at concentrations hundreds of times lower than those needed to interfere with the protective one.1Veterinary and Animal Science. Synopsis of the pharmacokinetics, pharmacodynamics, applications, and safety of firocoxib in horses That selectivity is the whole selling point: you get pain relief while largely sparing the gastrointestinal and kidney functions that COX-1 supports.2PubMed Central. Sparing the gut: COX-2 inhibitors herald a new era for treatment of horses with surgical colic For a species notoriously prone to gastric ulcers and colitis, that distinction matters a great deal.
Primary Uses in Horses
The most common reason veterinarians prescribe firocoxib for horses is osteoarthritis. Aging sport horses, retired racehorses, and pleasure horses with chronic joint degeneration all benefit from its anti-inflammatory and analgesic effects. In a large head-to-head trial comparing firocoxib paste with phenylbutazone paste in horses with naturally occurring osteoarthritis, roughly 85 percent of horses in both groups showed clinical improvement by day 14. The firocoxib group performed slightly better on measures of pain during joint manipulation, joint circumference, and range of motion, while overall lameness scores were similar between the two drugs.3PubMed. Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis In other words, firocoxib matches bute for general lameness control and may edge it out on certain joint-specific measures.
Beyond arthritis, firocoxib sees growing use around surgical procedures. After castration, firocoxib controlled pain and inflammation as effectively as flunixin meglumine and meloxicam in a comparative study, though flunixin had a slight practical advantage in that specific surgical context.4PubMed. Effects of Flunixin Meglumine, Firocoxib, and Meloxicam in Equines After Castration It is also increasingly used in horses recovering from colic surgery, particularly small intestinal strangulation, where gut healing is paramount and a non-selective NSAID can cause additional damage to already compromised intestinal tissue.
The Colic Surgery Angle
This is where firocoxib’s COX-2 selectivity becomes especially compelling. When a horse undergoes emergency surgery for a strangulating small intestinal obstruction, the bowel wall has already suffered serious injury from restricted blood flow. Healing that tissue depends in part on the protective prostaglandins produced by COX-1. Using a traditional NSAID like flunixin for post-operative pain suppresses those prostaglandins, potentially slowing mucosal repair and worsening endotoxemia, the leakage of bacterial toxins from damaged gut into the bloodstream.
A multicenter, blinded, randomized clinical trial compared firocoxib with flunixin meglumine in horses after small intestinal strangulating obstruction surgery. Pain scores between the two groups were not significantly different, so the drugs controlled post-operative pain equally well. But horses treated with flunixin had more than three times the risk of elevated plasma sCD14, a validated marker of endotoxemia, compared with those on firocoxib.5PubMed Central. Multicentre, blinded, randomised clinical trial comparing the use of flunixin meglumine with firocoxib in horses with small intestinal strangulating obstruction In practical terms, firocoxib gave the same pain relief without amplifying the endotoxin response that can tip a post-colic horse into a downward spiral. That finding has shifted practice at many equine hospitals toward preferring firocoxib over flunixin in surgical colic cases.
Standard Dosing and How It Reaches Steady State
The labeled dose of firocoxib for horses (via the Equioxx formulation) is 0.1 mg per kilogram of body weight given orally once every 24 hours. For a typical 500-kilogram horse, that works out to a 57-mg daily dose. Firocoxib has roughly 70 percent oral bioavailability in horses, meaning a good proportion of the drug reaches circulation after passing through the gut.6PubMed Central. Use of firocoxib for the treatment of equine osteoarthritis
One practical consideration is how long it takes the drug to build up to effective blood levels. At the standard daily dose without a loading dose, firocoxib takes several days to reach steady-state concentrations. Pharmacokinetic work has shown that administering a single higher loading dose on day one, followed by the standard 0.1 mg/kg daily, achieves the target blood concentration faster while maintaining relatively constant drug levels through the treatment course.7PubMed. Disposition of firocoxib in equine plasma after an oral loading dose and a multiple dose regimen Whether a loading dose is appropriate depends on the clinical situation; a horse in acute post-surgical pain needs rapid drug levels, whereas a horse starting chronic arthritis management may be fine building up over a few days. Your veterinarian will make that call.
Why Previcox Tablets Get Used Instead of Equioxx
Previcox is sold as chewable tablets for dogs in 57-mg and 227-mg strengths. Because a 500-kg horse’s daily firocoxib dose is in the same range as a single 57-mg tablet, the math is convenient and the tablet form can be substantially cheaper than the Equioxx paste syringe. Many equine veterinarians prescribe Previcox tablets off-label for this reason. The active ingredient and its chemistry are identical, so the pharmacological effect is the same. The key difference is regulatory: Previcox has not undergone the specific regulatory approval process for use in horses, meaning the manufacturer does not guarantee the same quality-control testing for equine patients. In practice, off-label Previcox use is widespread and generally accepted by the veterinary community, but it should only be done under direct veterinary guidance, especially for accurate dosing.
Dosing Precision Matters
With the Equioxx paste syringe, doses are dialed in by body weight. With Previcox tablets, you are working with fixed tablet sizes. A 227-mg tablet would be far too much for a horse at the standard dose (a 500-kg horse needs about 50 to 57 mg), so using the wrong tablet strength is a real overdose risk. Even among the 57-mg tablets, accurate body-weight estimation is important. Over-dosing an NSAID in a horse, even a selective one, multiplies the risk of gastrointestinal and kidney damage. If your vet prescribes Previcox tablets, confirm the exact tablet size and number with them, and weigh or tape your horse rather than guessing.
Safety Profile at Standard Doses
At the recommended therapeutic dose, firocoxib has a reassuring safety record. A study evaluating oral firocoxib at the standard dose in healthy horses found no changes on gastroscopic examination or in hematological tests.8PubMed Central. Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses A separate pilot study that compared gastric mucosal findings in horses receiving firocoxib (including at a higher dose) with those receiving flunixin meglumine found no glandular disease in any group and no progression of pre-existing squamous lesions after treatment.9PubMed Central. Gastroscopic Evaluation of Gastric Mucosa in Horses Treated With Flunixin Meglumine or High-Dose Firocoxib: A Descriptive Pilot Study These findings support the idea that firocoxib’s COX-2 selectivity translates into real-world gastric sparing, at least over short-to-medium treatment periods.
Kidney function is the other major concern with any NSAID. A study looking at long-term firocoxib use found no difference in blood urea nitrogen or creatinine concentrations between horses on firocoxib and those not receiving it, suggesting that sustained use did not measurably impair kidney function.10PubMed Central. Long‐Term Firocoxib Use in Horses That is encouraging news for owners whose horses need ongoing pain management, though it does not eliminate the need for periodic veterinary monitoring.
Risks and When Things Go Wrong
No NSAID is without risk, and firocoxib is no exception. The margin of safety is not infinite, and real problems arise under several circumstances.
- Overdose or prolonged high doses: Exceeding the recommended dose erodes firocoxib’s COX-2 selectivity. At higher concentrations, the drug begins to inhibit COX-1 as well, which strips away the gastrointestinal protection that makes it attractive in the first place. Accidental overdoses have occurred when owners confused Previcox tablet strengths or miscalculated body weight.
- Stacking NSAIDs: Giving firocoxib alongside another NSAID, say bute or Banamine left over from an earlier prescription, is one of the most dangerous mistakes. The combined COX-1 and COX-2 suppression dramatically raises the risk of gastric ulceration and right dorsal colitis. Never administer two NSAIDs simultaneously unless specifically directed by your vet, and allow a washout period when switching from one to another.
- Dehydration or kidney stress: A dehydrated horse or one with pre-existing kidney compromise is at elevated risk from any NSAID. Prostaglandins help maintain blood flow to the kidneys, and even COX-2-selective drugs can reduce renal perfusion when the animal is already volume-depleted. Horses in heavy work during hot weather, or those recovering from colic with reduced water intake, need careful NSAID management.
- Corticosteroid combinations: Using firocoxib concurrently with corticosteroids like dexamethasone increases the likelihood of gastrointestinal ulceration. Both drug classes suppress protective mechanisms in the gut lining through different pathways, and the combined effect is more than additive.
Right Dorsal Colitis and Other GI Complications
Right dorsal colitis (RDC) is the most feared gastrointestinal consequence of NSAID use in horses, and it deserves its own discussion because it can be life-threatening and is often diagnosed late. RDC develops when prostaglandin suppression damages the mucosal lining of the right dorsal colon. Acute signs include colic, loss of appetite, lethargy, fever, and diarrhea, with colic severity ranging from mild to severe and sometimes linked to feeding. Chronic cases present as weight loss, intermittent diarrhea, and fluid accumulation under the belly, with the colon wall becoming thickened and fibrotic, sometimes leading to impaction.11PubMed Central. Non-Steroidal Anti-Inflammatory Drugs and Associated Toxicities in Horses
Firocoxib’s COX-2 selectivity reduces the risk of RDC compared to phenylbutazone or flunixin, but it does not eliminate it entirely. Overdoses, extended treatment beyond recommended durations without veterinary oversight, or stacking with another NSAID can still cause it. The tricky part is that early signs of RDC, like mild intermittent colic and soft manure, are easy to dismiss. If your horse is on any NSAID long-term and develops these signs, a veterinary exam including abdominal ultrasound should happen promptly rather than waiting to see if things resolve.
Firocoxib in Breeding Mares
One area where firocoxib has a distinct advantage over other NSAIDs is in early pregnancy. During the first days after conception, the equine embryo migrates freely through the uterus. This mobility is critical for signaling the mare’s body to maintain the pregnancy rather than returning to cycle. Some NSAIDs can disrupt the uterine contractions that drive embryo movement, putting the pregnancy at risk.
A study comparing the effects of flunixin meglumine, firocoxib, and meloxicam on embryo mobility found that firocoxib was the only one of the three that did not alter embryo movement. The embryos of firocoxib-treated mares moved normally across repeated evaluations, while flunixin and meloxicam both interfered with uterine mobility patterns.12PubMed. The effect of flunixin meglumine, firocoxib and meloxicam on the uterine mobility of equine embryos This makes firocoxib the safest NSAID option when you need to manage pain or inflammation in a mare during the early embryonic period. Breeders and reproductive veterinarians have increasingly adopted it for this reason, particularly for mares that develop post-breeding endometritis and need anti-inflammatory support at a time when embryo survival is at stake.
Long-Term Use and Monitoring
Many horse owners need to give firocoxib for months or even indefinitely for chronic arthritis. The available evidence on long-term use is cautiously positive, with kidney markers remaining stable in horses on extended courses. However, no drug used for that long should go unmonitored. A reasonable approach includes periodic blood work to check kidney and liver values, along with clinical monitoring for appetite changes, manure consistency, and attitude.
It is worth noting that while firocoxib manages pain and inflammation, it does not reverse joint damage. Cartilage that has already degraded will not regenerate because you gave a better NSAID. Firocoxib makes the horse more comfortable and functional, but long-term management of osteoarthritis usually involves complementary strategies: joint injections, controlled exercise programs, weight management, and sometimes nutraceuticals like glucosamine or hyaluronic acid. Firocoxib controls the daily inflammatory burden so the horse can move well enough to benefit from those other interventions.
Competition and Regulatory Considerations
If your horse competes under any governing body, you need to know the withdrawal time for firocoxib before competition. Detection thresholds and withdrawal guidelines differ by organization (FEI, USEF, racing commissions), and they change periodically. Firocoxib has a longer elimination half-life than phenylbutazone, which means it stays in the horse’s system longer. A horse cleared of bute in a few days may still test positive for firocoxib for a longer window. Always check the current rules published by your specific governing body, because getting this wrong can result in disqualification and penalties regardless of whether the drug was given for legitimate medical reasons.
The off-label status of Previcox adds a wrinkle here as well. Some organizations specifically require that medications be from species-approved formulations. If the rules in your discipline require a product labeled for horses, you would need Equioxx rather than Previcox, even though the drug inside is the same. A quick conversation with your vet and a review of your competition rulebook before the show season will save headaches.
When Firocoxib Is Not the Right Choice
Despite its advantages, firocoxib is not appropriate for every horse or every situation. Horses with known kidney disease should use any NSAID with extreme caution, and firocoxib is no exception. Horses with a history of right dorsal colitis or significant gastric ulceration may still be at risk, even with a COX-2-selective drug, particularly if the underlying damage has not fully healed. Foals and very young horses metabolize drugs differently from adults, and dosing data for juvenile equines is more limited.
There are also scenarios where the speed of onset matters. For acute, severe colic pain in a field setting where injectable access is available, intravenous flunixin meglumine still gets drug into the bloodstream faster than an oral dose of firocoxib can. In those emergency moments, the rapid onset of IV flunixin may outweigh firocoxib’s GI-sparing profile. The decision is situational, and this is why having a veterinarian involved in real time, rather than relying on leftover medications in the barn, is always the better approach.